BioSpace News Archive

Realm Therapeutics plc (AIM: RLM) (the Company or Realm), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it publicly filed a registration statement with the United States Securities and Exchange Commission (the U.S. SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company’s ordinary shares on the Nasdaq Global Market (Nasdaq)

Sun Pharmaceutical Industries Ltd. and Churchill Pharmaceuticals, LLC. today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA® (abiraterone acetate).

GamaMabs Pharma announces the upcoming presentation of clinical data from the First-In-Human C101 phase Ia/Ib study of its GM102 antibody during the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 4 in Chicago, USA.

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix.

Mainstay Medical International plc announces that Mr. Hugh Kavanagh is to step down as Chief Financial Officer (“CFO”) and leave Mainstay with effect from 21 August 2018.

Centogene, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S.

OncoDNA is pleased to announce that it has signed a screening agreement with Kura Oncology, Inc.

MDxHealth SA announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and AssureMDx test for bladder cancer were presented in two moderated posters and one podium presentation at the American Urological (AUA) Annual Meeting 18-21 May in San Francisco.

M.A. MedAlliance SA has raised $37 million.

MDxHealth SA announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and AssureMDx test for bladder cancer were presented in two moderated posters and one podium presentation at the American Urological (AUA) Annual Meeting 18-21 May in San Francisco.